Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 12 (5), 592-600

Cost-effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

Affiliations
Review

Cost-effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

Ali Manouchehrinia et al. Curr Neurol Neurosci Rep.

Abstract

Multiple sclerosis (MS) is a leading cause of disability among young adults and has a significant economic impact on society. Although MS is not currently a curable disease, costly treatments known as disease-modifying therapies (DMTs) are available to reduce the disease impact in certain types of MS. In the current economic downturn, cost-effectiveness analysis (CEA) of therapies in MS has become an important part of the decision-making process in order to use resources efficiently in the face of the rapidly escalating costs of MS. While some studies have reported costs of DMTs at the level of cost-effectiveness thresholds, some have estimated their costs beyond the tolerance level of health care systems. On the basis of the current literature and given the difficulties in accurately assessing cost-effectiveness in diseases like MS, it is challenging to determine whether DMTs are cost-effective. Further population-based studies are required regarding the cost-effectiveness of therapies in MS.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

References

    1. Neurology. 2011 Jul 26;77(4):355-63 - PubMed
    1. Ann Neurol. 1996 Mar;39(3):285-94 - PubMed
    1. Clin Ther. 2011 Jul;33(7):914-25 - PubMed
    1. Lancet Neurol. 2010 Apr;9(4):438-46 - PubMed
    1. Mult Scler. 2009 Dec;15(12):1528-31 - PubMed

MeSH terms

Feedback